Literature DB >> 12744611

Medical management of melanoma.

Charles Komen Brown1, John M Kirkwood.   

Abstract

The treatment for malignant melanoma has undergone significant changes over the past few decades, with biological therapy playing an increasingly important role and replacing the traditional cytotoxic agents as the first-line therapy for this disease, both in advanced disease and adjuvant settings. Despite the developments of new modalities of therapy for melanoma, the outcome for patients with advanced disease remains poor. This article discusses the clinical studies that have shaped our current management of melanoma, both in the adjuvant setting, and in the metastatic setting. Additionally, successes and failures of clinical trials will be discussed, as they will guide the strategic development of future studies in the management of this aggressive disease.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12744611     DOI: 10.1016/S0039-6109(02)00187-1

Source DB:  PubMed          Journal:  Surg Clin North Am        ISSN: 0039-6109            Impact factor:   2.741


  5 in total

1.  TT-1, an analog of melittin, triggers apoptosis in human thyroid cancer TT cells via regulating caspase, Bcl-2 and Bax.

Authors:  Lanlan Wan; Daqi Zhang; Jinnan Zhang; Liqun Ren
Journal:  Oncol Lett       Date:  2017-11-08       Impact factor: 2.967

2.  Anti-hepatocarcinoma activity of TT-1, an analog of melittin, combined with interferon-α via promoting the interaction of NKG2D and MICA.

Authors:  Lan-Lan Wan; Da-Qi Zhang; Jin-Nan Zhang; Li-Qun Ren
Journal:  J Zhejiang Univ Sci B       Date:  2017-06       Impact factor: 3.066

3.  Inhibition of melanoma growth by subcutaneous administration of hTERTC27 viral cocktail in C57BL/6 mice.

Authors:  Longfei Huo; Hong Yao; Xicai Wang; Gee Wan Wong; Hsiang-fu Kung; Marie C Lin
Journal:  PLoS One       Date:  2010-09-13       Impact factor: 3.240

4.  The synthetic parasite-derived peptide GK1 increases survival in a preclinical mouse melanoma model.

Authors:  Armando Pérez-Torres; Jesús Vera-Aguilera; Juan Carlos Hernaiz-Leonardo; Eduardo Moreno-Aguilera; Diego Monteverde-Suarez; Carlos Vera-Aguilera; Daniel Estrada-Bárcenas
Journal:  Cancer Biother Radiopharm       Date:  2013-07-10       Impact factor: 3.099

5.  The multikinase inhibitor midostaurin (PKC412A) lacks activity in metastatic melanoma: a phase IIA clinical and biologic study.

Authors:  M J Millward; C House; D Bowtell; L Webster; I N Olver; M Gore; M Copeman; K Lynch; A Yap; Y Wang; P S Cohen; J Zalcberg
Journal:  Br J Cancer       Date:  2006-09-12       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.